We have experience of improving significantly the biovailability of poorly soluble active ingredients, particularly by forming solid dispersions. During the melt extrusion process, many drugs dissolve in the polymer in a solvent-free environment and then remain in a state of molecular dispersion as the polymer hardens.As a result, both dissolution kinetics and rate of absorption from the G.I. tract can be tailored to meet specific profiles and requirements.This improved biovailability confers therapeutic, pharmaceutical and commercial benefits for orally-administered products.The technology is particularly useful where the drug substance has a number of polymorphic forms each with different bioavailability.

We offer the development of specifically designed controlled release formulations (with profiles ranging from fast to modified to sustained release), all achieved by using conventional pharmaceutical polymers.By varying the type of polymer used, we can offer in vivo drug delivery in a time range of less than 5 minutes to more than 24 hours. Complex, near linear and even zero-order kinetics or pH-independent release may be achieved, if required. One example of this is our Verapamil 240 mg SR formulation which is sold on the European market. Other countries will follow.In addition improved biovailability may also be possible at the same time

< Back